Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Cipla Limited

Compensation For COVID-19 Vaccine Injuries In India: Stark Fault Lines?

Experts discuss the complexities of pursuing compensation for COVID-19 vaccine-related injuries in India. Is there a case for ‘absolute liability’ for all injuries related to the two fast-tracked vaccines currently available, or alternatively a no-fault compensation program?

Asia Pacific India

Compensation For COVID-19 Vaccine Injuries In India: Stark Fault Lines?

Scrip discusses with a cross-section of experts the complexities around pursuing compensation for COVID-19 vaccine-related injuries in India. Is there a case for ‘absolute liability’ for all injuries related to the two fast-tracked vaccines currently available, or alternatively a no-fault compensation program?

India Policy & Regulation

Biocon-CHAI Cancer Biosimilars Deal Promises Large Savings

Biocon Biologics strikes deal with the Clinton Health Access Initiative to provide cost-effective alternatives to pricey reference biologics, beginning with trastuzumab and pegfilgrastim. Savings of over 59% for buyers are expected in some cases.

Commercial Cancer

Lupin Expects Respiratory Ramp Up From Fiscal '22

After launching albuterol, India's Lupin is seeking to expand its presence in the respiratory market. With generic Fostair set for a European launch in fiscal 2022 and Spiriva for a US introduction the following fiscal year, the company is counting on the portfolio to deliver growth from the coming financial year.

Strategy Sales & Earnings
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Medical Devices
  • Pharmaceuticals
  • Services
    • Consulting Services
  • Pharmaceuticals
    • Drug Delivery
    • Generic Drugs
    • Nutraceuticals
    • Vaccines
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • Cipla Gulf FZ LLC
    • Cipla Technologies LLC
    • InvaGen Pharmaceuticals Inc.
    • Mirren Pty, Ltd.
UsernamePublicRestriction

Register